<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2048">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832841</url>
  </required_header>
  <id_info>
    <org_study_id>G-21-07</org_study_id>
    <nct_id>NCT04832841</nct_id>
  </id_info>
  <brief_title>IgG Antibodies After SARS-CoV-2 mRNA Vaccine in Kidney Transplantation (TASMANIA)</brief_title>
  <acronym>TASMANIA</acronym>
  <official_title>IgG Antibodies After SARS-CoV-2 mRNA Vaccine in Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess humoral immune response in kidney transplant recipients&#xD;
      after SARS-CoV-2 mRNA vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TASMANIA is a single-center prospective observational study with 1000 kidney transplant&#xD;
      recipients from Institute for Clinical and Experimental Medicine (IKEM), Prague. The primary&#xD;
      objective of the study is to assess humoral and cellular immune response to SARS-CoV-2 mRNA&#xD;
      vaccines in SARS-CoV-2-naive kidney transplant recipients using immunochemiluminescent and&#xD;
      Enzyme Linked Immuno Spot (ELISPOT) assays. As comparator several cohorts will be evaluated:&#xD;
&#xD;
        1. kidney transplant recipients with previous SARS-CoV-2 exposition verified by real-time&#xD;
           reverse transcription polymerase chain reaction (RT-PCR)&#xD;
&#xD;
        2. kidney transplant recipients vaccinated on waiting list (a) SARS-CoV-2 naive (b)&#xD;
           SARS-CoV-2 previously exposed&#xD;
&#xD;
      The secondary objective is to determine clinical variables affecting antibody levels.&#xD;
      SARS-CoV-2 anti S1/2 antibodies will be tested ≥ 15 days after the second dose of mRNA&#xD;
      vaccines and in 3 months after the first blood sampling.&#xD;
&#xD;
      In subanalysis 50 kidney transplant recipients will be examined for a cell-mediated immune&#xD;
      response after SARS-CoV-2 mRNA vaccine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Humoral immune response in kidney transplant recipients following anti-SARS-CoV2 mRNA vaccination.</measure>
    <time_frame>15 days-90 days</time_frame>
    <description>anti-spike SARS-CoV-2 IgG measured ≥15 days after vaccination and 3 ≥ months after the first blood sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft function after vaccination</measure>
    <time_frame>15 days-90 days</time_frame>
    <description>Estimated glomerular filtration rate (eGFR)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>SARS-CoV-2 naive</arm_group_label>
    <description>Kidney transplant recipients without previous SARS-CoV-2 infection verified by absence of RT-PCR test in national database who receive SARS-CoV-2 mRNA vaccine after transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SARS-Cov-2 exposed</arm_group_label>
    <description>Kidney transplant recipients with previous SARS-CoV-2 exposition verified by positivity of RT-PCR test in national database who receive SARS-CoV-2 mRNA vaccine after transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waiting list</arm_group_label>
    <description>Kidney transplant recipients who were vaccinated on waiting list (a) SARS-CoV-2 naive (b) SARS-Cov-2 exposed</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>anti-spike SARS-CoV-2 IgG</intervention_name>
    <description>Immunochemiluminescent assay by DiaSorin S.p.A. Italy</description>
    <arm_group_label>SARS-CoV-2 naive</arm_group_label>
    <arm_group_label>SARS-Cov-2 exposed</arm_group_label>
    <arm_group_label>Waiting list</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney transplant recipients vaccinated with 2 doses of SARS-CoV-2 mRNA vaccine either&#xD;
        before or after kidney transplantation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Kidney transplant recipients&#xD;
&#xD;
          -  Recipient age ≥ 18 years&#xD;
&#xD;
          -  Written Informed Consent and Consent for Processing Personal Data&#xD;
&#xD;
          -  Vaccination with two doses of SARS-CoV-2 mRNA vaccine either before or after kidney&#xD;
             transplantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active SARS-CoV-2 infection.&#xD;
&#xD;
          -  Patients that received anti-SARS-CoV-2 monoclonal antibodies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ondrej Viklicky, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Clinical and Experimental Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ondrej Viklicky, Prof.</last_name>
    <phone>+420261364110</phone>
    <email>ondrej.viklicky@ikem.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ondrej Viklicky, Prof.</last_name>
      <phone>261364110</phone>
      <phone_ext>+420</phone_ext>
      <email>ondrej.viklicky@ikem.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 3, 2021</study_first_submitted>
  <study_first_submitted_qc>April 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 3, 2021</last_update_submitted>
  <last_update_submitted_qc>April 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Prof. Ondřej Viklický, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Head of Department of Nephrology and Transplant Center</investigator_title>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>humoral immunity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

